Incyte JAKAFI — Loss contingency accrual increased by 12.5% to $245.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 69.1%, from $145.40M to $245.90M. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase suggests rising legal or operational risks, while a decrease indicates a resolution of disputes or reduced risk exposure.
This metric represents the amount reserved on the balance sheet to cover potential future losses related to legal or con...
Common in pharmaceutical companies facing litigation or regulatory scrutiny.
incy_segment_jakafi_loss_contingency_accrual| Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.90M | $59.50M | $73.70M | $91.10M | $106.90M | $127.60M | $145.40M | $165.20M | $188.90M | $218.50M | $245.90M |
| QoQ Change | — | +38.7% | +23.9% | +23.6% | +17.3% | +19.4% | +13.9% | +13.6% | +14.3% | +15.7% | +12.5% |
| YoY Change | — | — | — | — | +149.2% | +114.5% | +97.3% | +81.3% | +76.7% | +71.2% | +69.1% |